About
Diabetes-Targeting Biologics
Areas of Focus
Categories
Biologics & Biopharmaceutical
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
4
As Collaborator
6
Total Enrollment
633
By Phase
PHASE2: 5PHASE3: 1PHASE1/PHASE2: 2NA: 1PHASE1: 1
By Status
COMPLETED: 8RECRUITING: 2
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT05683990Lead Sponsor
Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals At Risk for Type 1 Diabetes
PHASE2Recruiting
16 participants
Started: Jul 9, 2024 · Completed: Dec 31, 2026
NCT05018585Lead Sponsor
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
PHASE3Recruiting
330 participants
Started: May 19, 2022 · Completed: Dec 31, 2027
NCT05351879Collaborator
Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes
PHASE1/PHASE2Completed
6 participants
Started: May 9, 2022 · Completed: Aug 29, 2023
NCT04262479Collaborator
Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes
PHASE2Completed
14 participants
Started: Mar 2, 2020 · Completed: May 5, 2022
NCT03635437Collaborator
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
PHASE1/PHASE2Completed
35 participants
Started: Sep 5, 2018 · Completed: Sep 27, 2022
Locations (1)
Headquarters
Stockholm, Sweden
Map
Loading map...